Gadopentetate-Dimeglumine 0.0125 mmol — Competitive Intelligence Brief

Gadopentetate-Dimeglumine 0.0125 mmol (Gadopentetate-Dimeglumine 0.0125 mmol) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Gadolinium-based contrast agent. Area: Diagnostic Imaging.

marketed Gadolinium-based contrast agent Water proton relaxation (T1 relaxation time) Diagnostic Imaging Small molecule

Target snapshot

Gadopentetate-Dimeglumine 0.0125 mmol (Gadopentetate-Dimeglumine 0.0125 mmol) — Paracelsus Medical University. Gadopentetate dimeglumine is a gadolinium-based contrast agent that accumulates in tissues and enhances magnetic resonance imaging (MRI) signal by altering the relaxation properties of water protons.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Gadopentetate-Dimeglumine 0.0125 mmol TARGET	Gadopentetate-Dimeglumine 0.0125 mmol	Paracelsus Medical University	marketed	Gadolinium-based contrast agent	Water proton relaxation (T1 relaxation time)
Gadavist	GADOBUTROL	Bayer	marketed	Gadolinium-based Contrast Agent [EPC]		2011-01-01
Gadopentetate-Dimeglumine 0.05 mmol	Gadopentetate-Dimeglumine 0.05 mmol	Paracelsus Medical University	marketed	Gadolinium-based contrast agent	Water protons (T1 relaxation enhancement)
MultiHance 0.05 mmol/kg	MultiHance 0.05 mmol/kg	Bracco Diagnostics, Inc	marketed	Gadolinium-based contrast agent	Water proton relaxation (T1 relaxation enhancement)
Gadoteric Acid Meglumine Salt	Gadoteric Acid Meglumine Salt	The Central Hospital of Lishui City	marketed	Gadolinium-based contrast agent	Water proton relaxation (T1 relaxation time)
Gadovist®/Gadavist®	Gadovist®/Gadavist®	Guerbet	marketed	Gadolinium-based contrast agent	Water proton relaxation (T1 relaxation enhancement)
gadoxetic acid enhanced liver MRI	gadoxetic acid enhanced liver MRI	Seoul National University Hospital	marketed	Gadolinium-based contrast agent	Organic anion transporter 1B1/1B3 (OATP1B1/1B3)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Gadolinium-based contrast agent class)

1. Guerbet · 4 drugs in this class
2. Bayer · 4 drugs in this class
3. Paracelsus Medical University · 2 drugs in this class
4. GE Healthcare · 1 drug in this class
5. Bracco Diagnostics, Inc · 1 drug in this class
6. Seoul National University Hospital · 1 drug in this class
7. Shanghai Shengdi Pharmaceutical Co., Ltd · 1 drug in this class
8. The Central Hospital of Lishui City · 1 drug in this class